Common pathways in idiopathic pulmonary fibrosis and cancer},

Carlo Vancheri

Source: Eur Respir Rev 2013; 22: 265-272
Journal Issue: September 2013 - 22 (129)
Disease area: Interstitial lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Carlo Vancheri. Common pathways in idiopathic pulmonary fibrosis and cancer},. Eur Respir Rev 2013; 22: 265-272

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Is toll like receptor 4 a common pathway hypothesis for development of lung cancer and idiopathic pulmonary fibrosis?
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016


The role of infection in the pathogenesis of idiopathic pulmonary fibrosis},
Source: Eur Respir Rev 2013; 22: 376-381
Year: 2013



Pulmonary hypertension in chronic interstitial lung diseases},
Source: Eur Respir Rev 2013; 22: 292-301
Year: 2013



Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis?
Source: Eur Respir J 2003 Dec 01;22(6):906-911
Year: 2003



Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future},
Source: Eur Respir Rev 2013; 22: 281-291
Year: 2013



Treatment of pulmonary exacerbations in cystic fibrosis},
Source: Eur Respir Rev 2013; 22: 205-216
Year: 2013



Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
Source: Eur Respir J 2007; 30: 835-839
Year: 2007



Unfolding the mechanisms of progression of pulmonary emphysema in COPD},
Source: Eur Respir J 2012; 40: 801-803
Year: 2012


The ratio AGE/RAGE is increased in idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015


Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016


Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases
Year: 2012

Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients},
Source: Eur Respir J 2012; 40: 630-640
Year: 2012



Significance of connective tissue diseases features in pulmonary fibrosis},
Source: Eur Respir Rev 2013; 22: 273-280
Year: 2013



Clinical profile of idiopathic pulmonary fibrosis with lung cancer
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011


Idiopathic pulmonary upper lobe fibrosis shows distinct features and poor prognosis compared to idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013


Severe pulmonary hypertension leading to heart–lung transplantation and revealing breast cancer},
Source: Eur Respir J 2012; 40: 1057-1059
Year: 2012


Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013

Interstital lung diseases: update 2005
Source: Annual Congress 2005 - Clinical year in review
Year: 2005

Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema
Source: Eur Respir J 2011; 37: 176-183
Year: 2011



Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013